Anti-PD1 antibody–mediated therapy for various tumors has shown great success in patients with cancer and has been recently found to be associated with the up-regulation of certain metabolites in responder (R) groups as compared to nonresponder (NR) groups (21, 24). This evidence concerns the gene RPL17 and cancer.